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Abstract 
Objective: To implement a Mendelian randomization (MR) approach to determine whether 
type 2 diabetes (T2D), fasting glucose, fasting insulin, and body mass index (BMI) are 
causally associated with specific ischemic stroke subtypes. 
Methods: MR estimates of the association between each possible risk factor and ischemic 
stroke subtypes were calculated using inverse-variance weighted (conventional) and weighted 
median approaches, and MR-Egger regression was used to explore pleiotropy. The number of 
single nucleotide polymorphisms utilized as instrumental variables was 49 for T2D, 36 for 
fasting glucose, 18 for fasting insulin, and 77 for BMI. Genome-wide association study data 
of SNP–stroke associations were derived from METASTROKE and the Stroke Genetics 
Network (N = 18,476 ischemic stroke cases and 37,296 controls). 
Results Conventional MR analysis showed associations between genetically predicted T2D 
and large artery stroke (odds ratio 1.28; 95% CI 1.16–1.40; p = 3.3 x 10-7) and small vessel 
stroke (odds ratio 1.21; 95% CI 1.10–1.33; p = 8.9 x 10-5) but not cardioembolic stroke (OR 
1.06; 95% CI 0.97–1.15; p = 0.17). The association of T2D with large artery stroke but not 
small vessel stroke was consistent in a sensitivity analysis using the weighted median method 
and there was no evidence of pleiotropy. Genetically predicted fasting glucose and fasting 
insulin levels and BMI were not statistically significantly associated with any ischemic stroke 
subtype.  
Conclusions: This study provides support for that T2D may be causally associated with large 
artery stroke. 
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Stroke is one of the leading causes of disability and death worldwide.1 The burden of stroke 
is projected to increase considerably in the next decades. Hence, there is a need to develop 
effective prevention strategies for stroke, which necessitates a better understanding of the 
underlying risk factors. About 80% of all strokes are ischemic,1 but this term describes a 
syndrome caused by a number of different pathologies, which may have different treatments.2 
The major etiologies of ischemic stroke are large artery atherosclerosis (large artery stroke), 
small vessel atherosclerosis (small vessel stroke) and cardioembolism (cardioembolic stroke). 
Recent data from genome-wide association studies (GWAS) have shown that these subtypes 
have distinctive risk factor profiles, and by implication diverse pathophysiological bases.3  
Type 2 diabetes (T2D) is associated with an increased risk of ischemic stroke4 but its 
relative contribution to different ischemic stroke subtypes is unknown. Moreover, several risk 
factors that are highly correlated with T2D, including hyperglycemia, insulin resistance, and 
body mass index (BMI), have been associated with risk of stroke in observational studies.5, 6 
However, the causality of the association between these metabolic factors and stroke risk is 
uncertain because of the high correlations between these factors, and the associations may be 
confounded by an unhealthy diet or other behavioral or environmental risk factors. Whether 
elevated fasting glucose and insulin levels and BMI have different associations with different 
ischemic stroke subtypes are unknown.  
The technique of Mendelian randomization (MR) is being increasingly used to examine 
causality of associations between modifiable risk factors and various diseases, particularly 
where confounding is of concern. It uses genetic variants (single nucleotide polymorphisms; 
SNPs) as instrumental variables for estimating the effect of a risk factor on a disease risk. 
Because genotypes are randomly allocated during meiosis, the population genotype 
distribution should be unrelated to any confounders.7 In this respect, MR can be thought of as 
a natural randomized controlled trial. In the present study, MR was implemented to determine 
Larsson'
''
5'
whether T2D, glucose, insulin, and BMI are causally associated with all ischemic stroke, and 
with its three main subtypes; large artery, small vessel, and cardioembolic stroke.  
 
Methods 
Study design and data sources  
This MR analysis was conducted using summary statistics from two large ischemic stroke 
genetics consortia: the METASTROKE Collaboration3, 8 and the National Institute of 
Neurological Disorders and Stroke (NINDS)-Stroke Genetics Network (SiGN).9 GWAS from 
these consortia contributed a total of 18,476 ischemic stroke cases and 37,296 controls of 
mainly European ancestry. Overlapping participants in the two consortia were removed. The 
TOAST classification system was used for stroke subtyping,10 identifying 2947 large artery 
strokes, 2757 small vessel strokes, and 3860 cardioembolic strokes. In addition, there were 
8912 undetermined strokes (cases in which the stroke mechanism had not been identified) 
and multiple pathologies strokes. All cases were ischemic stroke and had brain imaging to 
confirm this and to exclude a hemorrhage. The majority of stroke cases were prevalent cases. 
Genotyping was performed using a variety of Illumina or Affymetrix platforms. All cohorts 
underwent genotype imputation using 1000 Genomes (1 KG) phase I reference panel prior to 
meta-analysis.8, 11 Data from NINDS-SiGN were imputed to a merged reference panel that 
included the 1000 Genomes Project Phase I and the Genome of the Netherlands.12  
 
Standard Protocol Approvals, Registrations, and Patient Consents 
Each study included in the stroke consortia was approved by an Institutional Review Board, 
and all patients provided informed consent.  
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SNP selection 
We selected all SNPs associated with T2D,13-16 fasting glucose,17 fasting insulin,17 and BMI18 
at genome-wide significance threshold (p < 5 x 10-8) in individuals of European ancestry in 
previously published large-scale GWAS. Because the effects of FTO variants on T2D and 
fasting insulin appear to be mediated solely by BMI,17 SNPs from this locus were excluded 
from the analyses of T2D and fasting insulin to avoid possible confounding by BMI. Thus, 
the number of SNPs used as instrumental variables in the present analyses was 49 for T2D, 
36 for fasting glucose, 18 for fasting insulin, and 77 for BMI (i.e., SNPs associated with BMI 
in the primary meta-analysis of European-descent individuals) (Table e-1). All SNPs within 
each trait were uncorrelated (not in linkage disequilibrium). 
 
Statistical analysis 
Summary statistics for the association of each SNP with the risk factors and ischemic stroke 
as a whole and the three main subtypes (large artery, small vessel, and cardioembolic strokes) 
were acquired, respectively, from previously published GWAS of the risk factors13-18 and two 
stroke consortia (METASTROKE and NINDS-SiGN).8, 9 The “SNP–risk factor” and “SNP–
stroke” associations were used to compute estimates of each “risk factor–stroke” association 
using an inverse-variance weighted method19 (hereafter referred to as conventional MR 
analysis). We conducted complementary analyses using the weighted median'and MR-Egger 
regression methods.20, 21 MR-Egger regression can identify and control for bias due to 
directional pleiotropy (i.e., where the genetic variant has a direct effect on the outcome that is 
not mediated by the exposure).20 In sensitivity analyses, we assessed the robustness of the 
results by excluding loci that overlapped between the four metabolic traits assessed in this 
study and by excluding SNPs associated with blood lipids22, 23 and smoking24 (Table e-1).  
Results of the MR analyses are presented per genetically predicted one-unit higher log-
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odds of T2D and one standard deviation (SD) increase in fasting glucose (0.65 mmol/L) and 
natural log-transformed fasting insulin (0.60 pmol/L). The SDs used for scaling of the results 
for glucose and insulin were derived from the population-based Fenland25 and Ely26 studies. 
Because the GWAS of BMI estimated the SNP-BMI associations using inverse normal 
transformation, the MR estimates can be interpreted as the odds ratio (OR) per 1-SD 
increment in BMI. All statistical tests were 2-sided and considered statistically significant at 
Bonferroni-corrected significance threshold (p = 0.05/16 tests = 0.003). The analyses were 
performed in Stata version 14.1 (StataCorp, College Station, Texas, USA).  
 
Results  
The associations between each genetically predicted risk factor and all ischemic strokes and 
ischemic stroke subtypes, using conventional MR analysis, are presented in Figure 1. T2D 
was associated with a higher odds of all ischemic stroke (OR 1.12; 95% CI 1.07–1.17; p = 
3.0 x 10-6), large artery stroke (OR 1.28; 95% CI 1.16-1.40; p = 3.3 x 10-7), and small vessel 
stroke (OR 1.21; 95% CI 1.10–1.33; p = 8.9 x 10-5) but not with cardioembolic stroke (OR 
1.06; 95% CI 0.97–1.15; p = 0.17). The association of T2D with large artery stroke but not 
small vessel stroke was consistent in complementary analysis using the weighted median 
method (Table e-2). Results from the MR-Egger regression analysis, which has lower 
statistical power, yielded a similar OR for T2D and large artery stroke but the CI was wide 
and included the null (Table e-2). MR-Egger regression analysis provided no evidence of 
directional pleiotropy for the associations of T2D with large artery stroke (intercept = 0.003; 
p = 0.82), small vessel stroke (intercept = 0.008; p = 0.50), or cardioembolic stroke (intercept 
= 0.005; p = 0.62).  
Genetically predicted higher fasting glucose was associated with a higher odds of large 
artery stroke in conventional MR analysis (Figure 1) but the result did not remain statistically 
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significant after Bonferroni correction and no statistically significant association was 
observed in the weighted median and MR-Egger regression analyses (Table e-2). A similar, 
non-significant association was found between fasting insulin and large artery stroke (Figure 
1 and Table e-2). Fasting glucose and fasting insulin were not associated with small vessel or 
cardioembolic strokes, and there were no associations between BMI and all ischemic strokes 
or any subtype (Figure 1 and Table e2).  
We conducted a series of sensitivity analyses to assess the robustness of the results (Table 
e-3). First we excluded the TCF7L2 locus, which was associated with large artery stroke as 
well as strongly with T2D and weakly with the other three traits (Table e-1). Exclusion of this 
locus did not appreciably change the results for T2D and large artery stroke (OR 1.25; 95% 
CI 1.13–1.39; p = 3.3 x 10-5). Removing loci that overlapped between the four traits also did 
not materially alter the results for T2D and large artery stroke (OR 1.32; 95% CI 1.14–1.53; p 
= 2.5 x 10-4) or any of the other findings (Table e-3). In a further sensitivity analysis, we 
excluded SNPs associated with lipids (low-density lipoprotein cholesterol, high-density 
lipoprotein cholesterol, total cholesterol, or triglycerides) at genome-wide significance level. 
In this analysis the association between T2D and large artery stroke remained (OR 1.29; 95% 
CI 1.17–1.42; p = 6.0 x 10-7) and the associations of the other three traits with ischemic 
stroke did not change appreciably (Table e-3). Finally, the lack of association between BMI 
and all ischemic stroke and its subtypes remained after removing the BDNF locus, which has 
been found to be associated with smoking (Table e-3). 
 
Discussion 
This MR study showed a robust association between genetic predisposition to T2D and large 
artery stroke but not small vessel or cardioembolic strokes. It did not provide clear evidence 
for a causal role of fasting glucose, fasting insulin, and BMI in any ischemic stroke subtype.  
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Studies of the association between T2D and etiologic subtypes of ischemic stroke are rare, 
but several previous observational studies have investigated the association between T2D and 
risk of all ischemic strokes or total stroke (ischemic and hemorrhagic strokes combined). For 
example, in a prospective cohort of 1.9 million people, T2D was associated with a 72% 
increased risk of all ischemic strokes.4 Furthermore, in a meta-analysis of 64 observational 
prospective studies, representing 775,385 individuals and 12,539 stroke cases, the overall 
relative risks of total stroke for individuals with diabetes versus non-diabetics were 2.28 
(95% CI 1.93–2.69) in women and 1.83 (95% CI 1.60–2.08) in men.27  
T2D is associated with insulin resistance and elevated insulin levels during the early 
stages of the disease. Eventually the pancreas is no longer able to compensate the insulin 
resistance by secreting sufficient insulin to keep blood glucose level within the normal range, 
thereby resulting in hyperglycemia. A meta-analysis of 14 prospective studies reported a 
statistically significant 44% increased risk of total stroke for high versus low fasting glucose 
levels.6 Insulin resistance was associated with a 76% increased risk of stroke (based on four 
studies) and high versus low fasting insulin was associated with a non-significant 90% higher 
risk (based on two studies).6  
The value of intensive glucose-lowering therapy for cardiovascular disease prevention in 
patients with T2D was questioned since two randomized controlled trials failed to show a 
reduction in major vascular events, including stroke,28, 29'and even increased mortality29 with 
the use of intensive glucose control compared with standard therapy. The present MR study 
found no clear support for a causal role of fasting glucose in any ischemic stroke subtype. 
Genetically predicted fasting glucose was associated with large artery stroke at nominal 
statistical significance in the conventional MR analysis but this association did not remain in 
the MR-Egger regression analysis.  
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A randomized controlled trial that investigated the effect of pioglitazone, which improves 
insulin sensitivity, on cardiovascular events in patients with insulin resistance but without 
T2D showed a 24% reduced risk of the composite primary outcome of stroke and myocardial 
infarction in the pioglitazone arm compared with placebo over a median follow-up of 4.8 
years.30 In this MR analysis, genetically predicted higher fasting insulin was associated with a 
non-significant higher odds of large artery stroke.  
The lack of clear association between genetically predicted fasting glucose and insulin 
and large artery stroke suggests that other pathways might explain the association with T2D. 
Observational studies have reported that T2D is associated with increased arterial stiffness,31, 
32 which is a risk factor for stroke.33 In addition, a causal association between T2D and 
arterial stiffness was found in a recent MR study.34 Stiffening of the arteries may result in the 
development of atherosclerotic carotid plaques35 and increased risk of large artery stroke.36  
The present study did not detect a statistically significant association between genetically 
predicted BMI and ischemic stroke or its subtypes. Results from a recent meta-analysis of 6 
cohort studies conducted in Europe, the United States, and Australia, with a total of 14,443 
ischemic stroke cases, showed a 22% increase in ischemic stroke risk per 5-kg/m2 increment 
of BMI.5 Because our MR study had limited statistical power to detect such a small increase 
in risk, we cannot rule out the possibility of a causal association between BMI and ischemic 
stroke. A previous MR study, including 23,782 participants and 3813 stroke cases, observed 
no association between a genetic instrument comprising 14 BMI-associated SNPs and risk of 
all strokes (OR 1.03; 95% CI 0.95–1.12, per 1 kg/m2 increase in BMI).37 However, another 
MR study, including 20 055 participants and 1500 ischemic stroke cases, found a statistically 
significant association of genetically predicted higher BMI, based on a genetic instrument 
comprising 32 BMI-associated SNPs, with increased risk of ischemic stroke (hazard ratio 
1.83; 95% CI 1.05–3.20, per 4.5 kg/m2 increment of BMI).38  
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Chief strengths of this study include the large number of total ischemic stroke cases and 
data on etiologic subtypes of ischemic stroke. Moreover, because of the MR design, reverse 
causation bias was prevented and potential confounding was reduced because genetic variants 
are not associated with self-selected dietary and lifestyle factors that may affect results from 
observational studies.  
The MR approach also has limitations. First, pleiotropy (i.e., the genetic association with 
the outcome is through a different causal pathway and not via the risk factor of interest) could 
have influenced our results. However, our main finding for T2D and large artery stroke was 
consistent in sensitivity analyses using the weighted median and MR-Egger methods, and 
remained after excluding pleiotropic SNPs associated with lipids. MR-Egger regression 
provides a valid test of directional pleiotropy, and a valid test of the causal null hypothesis, 
under the InSIDE assumption that the direct pleiotropic effects of the genetic variants on the 
outcome are distributed independently of the genetic association with the exposure.20 Second, 
we could not assess whether canalization (i.e. compensatory mechanisms)7 may have affected 
our results. Canalization tends to attenuate the estimates and thus cannot explain the 
association between T2D and large artery stroke but might have contributed to the lack of 
association of the other risk factors with ischemic stroke. Third, we cannot entirely rule out 
population stratification as a source of bias in this study. Nevertheless, restriction of the data 
to largely European-descent individuals reduced potential bias due to population 
stratification. Fourth, the MR assumptions are somewhat stricter for binary exposures like 
T2D than for continuous exposures. For MR analysis of binary exposures, the monotonicity 
assumption must hold.39 Within the context of MR, the monotonicity assumption implies that 
any effect of the genetic instrument on the exposure is in the same direction for all persons. 
We cannot rule out the possibility that our results for T2D may have been biased due to 
monotonicity violations.  
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A further limitation is that the genetic variants associated with the risk factors under 
study only explain a small fraction of the variation in the risk factors. For example, the BMI-
associated SNPs account for less than 3% of the variation in BMI.18 This low variability 
together with the relatively small sample sizes for the analyses of ischemic stroke subtypes, 
resulted in low precision. Thus, we cannot exclude that the lack of significant associations of 
fasting glucose, fasting insulin, and BMI with ischemic stroke subtypes are due to insufficient 
statistical power. Another limitation is that the genetic effects on fasting glucose and insulin 
were estimated in individuals without diabetes, whereas our analyses included both diabetics 
and non-diabetics. Finally, we could not examine potential non-linear relationships for the 
continuous risk factors.      
This MR study indicates that T2D may be a causal risk factor for large artery stroke, but 
did not confirm the results of observational studies suggesting that higher fasting glucose, 
fasting insulin, and BMI are associated with an increased risk of ischemic stroke. Further MR 
studies with larger sample sizes are required to determine whether glucose, insulin, and BMI 
are causally associated with any ischemic stroke subtype.  
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FIGURE LEGEND 
 
Figure 1. Mendelian randomization estimates of the association between each genetically 
predicted risk factor and ischemic stroke and its subtypesa  
BMI, body mass index; CI, confidence interval; OR, odds ratio; T2D, type 2 diabetes. 
aAnalyses were performed using conventional Mendelian randomization analysis (inverse-
variance weighted method). The scaling of the odds ratios was one unit higher log-odds for 
type 2 diabetes and one standard deviation increase for fasting glucose, fasting insulin, and 
BMI. 
bNumber of cases/controls in parenthesis.   
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